

## 7 Literatur

1. Nagel, E., A.C. van Rossum, and E. Fleck, *Kardiovaskuläre Magnetresonanztomographie*. 2002, Darmstadt: Steinkopff-Verlag Darmstadt.
2. Sechtem, U., *Magnetresonanztomographie in der Kardiologie. Empfehlungen der Kommission für klinische Kardiologie der Deutschen Gesellschaft für Kardiologie--Herz- und Kreislaufforschung*. *Z Kardiol*, 1999. 88(11): p. 965-7.
3. Yucel, E.K., et al., *AHA scientific statement. Magnetic resonance angiography : update on applications for extracranial arteries*. *Circulation*, 1999. 100(22): p. 2284-301.
4. Nagel, E., et al., *Stress cardiovascular magnetic resonance: consensus panel report*. *J Cardiovasc Magn Reson*, 2001. 3(3): p. 267-81.
5. Shan, K., et al., *Role of cardiac magnetic resonance imaging in the assessment of myocardial viability*. *Circulation*, 2004. 109(11): p. 1328-34.
6. Edelman, R.R., et al., *Coronary arteries: breath-hold MR angiography*. *Radiology*, 1991. 181(3): p. 641-3.
7. Manning, W.J., et al., *Fat-suppressed breath-hold magnetic resonance coronary angiography*. *Circulation*, 1993. 87(1): p. 94-104.
8. Berman, D.S., et al., *Roles of nuclear cardiology, cardiac computed tomography, and cardiac magnetic resonance: Noninvasive risk stratification and a conceptual framework for the selection of noninvasive imaging tests in patients with known or suspected coronary artery disease*. *J Nucl Med*, 2006. 47(7): p. 1107-18.
9. Colletti, P.M., *Cardiac imaging 2006*. *AJR Am J Roentgenol*, 2006. 186(6 Suppl 2): p. S337-9.
10. Knollmann, F.D., et al., *Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography. Preliminary results of an animal study original investigation*. *Invest Radiol*, 1998. 33(9): p. 637-43.
11. Reimer, P., et al., *SPIO-enhanced 2D-TOF MR angiography of the portal venous system: results of an intraindividual comparison*. *J Magn Reson Imaging*, 1997. 7(6): p. 945-9.
12. Schmitz, S.A., et al., *SPIO-unterstützte MR-Angiographie des portalvenösen Systems*. *RöFo*, 2000. 172(1): p. 51-4.

13. Schmitz, S.A., T. Albrecht, and K.J. Wolf, *MR angiography with superparamagnetic iron oxide: feasibility study*. Radiology, 1999. 213(2): p. 603-7.
14. Schmitz, S.A., et al., *SPIO-unterstützte MR-Angiographie zur Detektion venöser Thromben im Tiermodell*. RöFo, 1999. 170(3): p. 316-21.
15. Tombach, B., et al., *First-pass and equilibrium-MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study*. NMR Biomed, 2004. 17(7): p. 500-6.
16. Allkemper, T., et al., *Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits*. Radiology, 2002. 223(2): p. 432-8.
17. Prince, M.R., Zhang, H.L., Chabra, *A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI*. J X-Ray Science Tech, 2003. 11: p. 231-240.
18. Saini, S., et al., *Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system*. Radiology, 1987. 162(1 Pt 1): p. 211-6.
19. Lawaczeck, R., et al., *Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting. Pre-clinical profile of SH U555A*. Acta Radiol, 1997. 38(4 Pt 1): p. 584-97.
20. Kreft, B.P., et al., *Contrast-enhanced MR imaging of diffuse and focal splenic disease with use of magnetic starch microspheres*. J Magn Reson Imaging, 1994. 4(3): p. 373-9.
21. Saeed, M., et al., *Value of blood pool contrast agents in magnetic resonance angiography of the pelvis and lower extremities*. Eur Radiol, 1998. 8(6): p. 1047-53.
22. Lacava ZGM, A.R., Lacava LM, Martins EV, Garcia VAP, Rébula CA, Lemos APC, Sousa MH, Tourinho FA, Moraris PC, M.F. DS, *Toxic effects of ionic magnetic fluids in mice*. J Magn Mag Mat, 1999. 194(194): p. 90-95.
23. Wagner, S., et al., *Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization*. Invest Radiol, 2002. 37(4): p. 167-77.
24. Muller, R.D., et al., *SPIO-MR imaging versus double-phase spiral CT in detecting malignant lesions of the liver*. Acta Radiol, 1999. 40(6): p. 628-35.
25. Reimer, P., et al., *Experimental hepatocellular carcinoma: MR receptor imaging*. Radiology, 1991. 180(3): p. 641-5.

26. Reimer, P., et al., *Receptor imaging: application to MR imaging of liver cancer*. Radiology, 1990. 177(3): p. 729-34.
27. Miyazaki, T., et al., *MR cholangiopancreatography using HASTE (half-Fourier acquisition single-shot turbo spin-echo) sequences*. AJR Am J Roentgenol, 1996. 166(6): p. 1297-303.
28. Wallner, B.K., et al., *Dilated biliary tract: evaluation with MR cholangiography with a T2-weighted contrast-enhanced fast sequence*. Radiology, 1991. 181(3): p. 805-8.
29. Lim, T.H., D. Saloner, and C.M. Anderson, *Current applications of magnetic resonance vascular imaging*. Cardiol Clin, 1989. 7(3): p. 661-83.
30. Hamm, B., et al., *Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide*. J Magn Reson Imaging, 1994. 4(5): p. 659-68.
31. Wang, Y., S.J. Riederer, and R.L. Ehman, *Respiratory motion of the heart: kinematics and the implications for the spatial resolution in coronary imaging*. Magn Reson Med, 1995. 33(5): p. 713-9.
32. Saini, S., et al., *Magnetism: a primer and review*. AJR Am J Roentgenol, 1988. 150(4): p. 735-43.
33. Weinmann, H.J., et al., *Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent*. AJR Am J Roentgenol, 1984. 142(3): p. 619-24.
34. Stuber, M., et al., *Contrast agent-enhanced, free-breathing, three-dimensional coronary magnetic resonance angiography*. J Magn Reson Imaging, 1999. 10(5): p. 790-9.
35. Bremer, C., et al., *RES-specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR-angiography*. J Magn Reson Imaging, 1999. 10(3): p. 461-7.
36. Wang, Y.X., S.M. Hussain, and G.P. Krestin, *Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging*. Eur Radiol, 2001. 11(11): p. 2319-31.
37. Kobozev, N.I., Evdokimov, V.B., *Magnetochemistry of active centers. I. Magnetic and catalytic properties of dilute layers*. Zhur Fiz Khim, 1952. 26: p. 1349-1373.
38. McLachlan, S.J., et al., *Phase I clinical evaluation of a new iron oxide MR contrast agent*. J Magn Reson Imaging, 1994. 4(3): p. 301-7.

39. Tombach, B., et al., *First-pass and equilibrium phase MRA following intravenous bolus injection of SH U 555 C: Phase I clinical trial in elderly volunteers with risk factors for arterial vascular disease*. Acad Radiol, 2002. 9 Suppl 2: p. S425-7.
40. Sako, M. and S. Hirota, [*Embolotherapy of hepatomas using ferromagnetic microspheres, its clinical evaluation and the prospect of its use as a vehicle in chemoembolo-hyperthermic therapy*]. Gan To Kagaku Ryoho, 1986. 13(4 Pt 2): p. 1618-24.
41. Sahani, D., et al., *Dynamic T1-weighted ferumoxides enhanced MRI for imaging liver hemangiomas: preliminary observations*. Abdom Imaging, 2001. 26(2): p. 166-70.
42. Wielopolski, P.A., et al., *Breath-hold coronary MR angiography with volume-targeted imaging*. Radiology, 1998. 209(1): p. 209-19.
43. Pauser, S., et al., *Liposome-encapsulated superparamagnetic iron oxide particles as markers in an MRI-guided search for tumor-specific drug carriers*. Anticancer Drug Des, 1997. 12(2): p. 125-35.
44. Hemmingsson, A., et al., *Relaxation enhancement of the dog liver and spleen by biodegradable superparamagnetic particles in proton magnetic resonance imaging*. Acta Radiol, 1987. 28(6): p. 703-5.
45. Anzai, Y., et al., *MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent*. J Magn Reson Imaging, 1997. 7(1): p. 209-14.
46. Anzai, Y. and M.R. Prince, *Iron oxide-enhanced MR lymphography: the evaluation of cervical lymph node metastases in head and neck cancer*. J Magn Reson Imaging, 1997. 7(1): p. 75-81.
47. Seneterre, E., et al., *Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging*. Radiology, 1991. 179(2): p. 529-33.
48. Pilgrimm, H., *Superparamagnetic particles with increased R1 relaxivity, their production and their use*. Patent: WO 9735200, 1997.
49. Massart, R., E. Dubois, and V. Cabuil, *Preparation and properties of monodisperse magnetic fluids*. J Magnetism Magn Mater., 1995. 149: p. 1-5.
50. Weissleder, R., et al., *Superparamagnetic iron oxide: pharmacokinetics and toxicity*. AJR Am J Roentgenol, 1989. 152(1): p. 167-73.

51. Tang, J., Myers, M., Bosnick, K.A., Brus, L.E., *Magnetite Fe<sub>3</sub>O<sub>4</sub> Nanocrystals: Spectroscopic Observation of Aqueous Oxidation Kinetics*. . J Phys Chem B 2003(107): p. 7501-7506.
52. Massart, R., Dubois, E., Cabuil, V., Hasmonay, E., *Preparation and properties of monodisperse magnetic fluids*. J Magn Magn Mater, 1995. 149: p. 1-5.
53. Bee, A., Massart, R., Neveu, S., *Synthesis of very fine maghemite particles*. J Magn Magn Mater, 1995. 149: p. 6-9.
54. Pilgrimm, H., *Stabilized suspension of magnetic particles and its preparation and use in NMR diagnosis*. Patent: DE 3709851, 1988.
55. Hasegawa, M., Hokukoku, S., *Magnetic iron oxide-dextran complex and process for its production*. Patent: US 4.101.435, 1978.
56. Bulte, J.M., et al., *Frequency dependence of MR relaxation times. II. Iron oxides*. J Magn Reson Imaging, 1993. 3(4): p. 641-8.
57. Port, M., et al., *P792: a rapid clearance blood pool agent for magnetic resonance imaging: preliminary results*. Magma, 2001. 12(2-3): p. 121-7.
58. Taupitz, M., et al., *New generation of monomer-stabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: preclinical results in rats and rabbits*. J Magn Reson Imaging, 2000. 12(6): p. 905-11.
59. Forth, W., D. Henschler, and W. Rummel, *Pharmakologie und Toxikologie*. 1983, Bibliographisches Institut, Mannheim, Wien, Zürich.
60. Dirksen, M.S., et al., *Toward comparability of coronary magnetic resonance angiography: proposal for a standardized quantitative assessment*. Eur Radiol, 2003. 13(10): p. 2353-7.
61. Taupitz, M., et al., *Coronary MR angiography: experimental results with a monomer-stabilized blood pool contrast medium*. Radiology, 2002. 222(1): p. 120-6.
62. Shen, T., et al., *Monocrystalline iron oxide nanocompounds (MION): physico-chemical properties*. Magn Reson Med, 1993. 29(5): p. 599-604.
63. Larsson, E.M., et al., *MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage*. AJR Am J Roentgenol, 2003. 180(1): p. 227-32.

64. Leiner, T., et al., *Multicenter phase-II trial of safety and efficacy of NC100150 for steady-state contrast-enhanced peripheral magnetic resonance angiography*. Eur Radiol, 2003. 13(7): p. 1620-7.
65. Reimer, P. and T. Balzer, *Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications*. Eur Radiol, 2003. 13(6): p. 1266-76.
66. Anzai, Y., et al., *Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study*. Radiology, 2003. 228(3): p. 777-88.
67. Rubin, D.L., et al., *A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial*. J Magn Reson Imaging, 1999. 9(2): p. 240-50.
68. Bluemke, D.A., et al., *Carotid MR angiography: phase II study of safety and efficacy for MS-325*. Radiology, 2001. 219(1): p. 114-22.
69. Idee, J.M., et al., *Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation*. Biometals, 1998. 11(2): p. 113-23.
70. Muhler, A., et al., *Amelioration of cardiodepressive effects of gadopentetate dimeglumine with addition of ionic calcium*. Radiology, 1992. 184(1): p. 159-64.
71. Bluemke, D.A., et al., *Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol*. Radiology, 2003. 228(2): p. 457-64.
72. Taylor, A.M., et al., *Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography*. J Magn Reson Imaging, 1999. 9(2): p. 220-7.
73. Weissleder, R., et al., *Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging*. Radiology, 1988. 169(2): p. 399-403.
74. Johansson, L.O., S.E. Fischer, and C.H. Lorenz, *Benefit of T1 reduction for magnetic resonance coronary angiography: a numerical simulation and phantom study*. J Magn Reson Imaging, 1999. 9(4): p. 552-6.

75. Zheng, J., et al., *Contrast-enhanced coronary MR angiography: relationship between coronary artery delineation and blood T1*. J Magn Reson Imaging, 2001. 14(4): p. 348-54.
76. Lorenz, C.H. and L.O. Johansson, *Contrast-enhanced coronary MRA*. J Magn Reson Imaging, 1999. 10(5): p. 703-8.
77. Corot, C., et al., *Comparison of different types of blood pool agents (P792, MS325, USPIO) in a rabbit MR angiography-like protocol*. Invest Radiol, 2003. 38(6): p. 311-9.
78. Schnorr, J., et al., *MR-Angiographie der Koronararterien: Vergleich des Blut-poolkontrastmittels Gadomer mit Gd-DTPA am Schwein*. RöFo, 2003. 175(6): p. 822-9.
79. Herborn, C.U., et al., *Coronary arteries: contrast-enhanced MR imaging with SH L 643A--experience in 12 volunteers*. Radiology, 2003. 229(1): p. 217-23.
80. Wagenseil, J.E., L.O. Johansson, and C.H. Lorenz, *Characterization of t1 relaxation and blood-myocardial contrast enhancement of NC100150 injection in cardiac MRI*. J Magn Reson Imaging, 1999. 10(5): p. 784-9.
81. La Noce, A., et al., *B22956/1, a new intravascular contrast agent for MRI: first administration to humans--preliminary results*. Acad Radiol, 2002. 9 Suppl 2: p. S404-6.
82. Taupitz, M., S. Schmitz, and B. Hamm, *[Superparamagnetic iron oxide particles: current state and future development]*. RöFo, 2003. 175(6): p. 752-65.
83. Kellar, K.E., et al., *NC100150 Injection, a preparation of optimized iron oxide nanoparticles for positive-contrast MR angiography*. J Magn Reson Imaging, 2000. 11(5): p. 488-94.
84. Clarke, S.E., et al., *Comparison of two blood pool contrast agents for 0.5-T MR angiography: experimental study in rabbits*. Radiology, 2000. 214(3): p. 787-94.
85. Wang, Y., et al., *Navigator-echo-based real-time respiratory gating and triggering for reduction of respiration effects in three-dimensional coronary MR angiography*. Radiology, 1996. 198(1): p. 55-60.
86. Botnar, R.M., et al., *Improved coronary artery definition with T2-weighted, free-breathing, three-dimensional coronary MRA*. Circulation, 1999. 99(24): p. 3139-48.

87. Misselwitz, B., et al., *Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent*. Magma, 2001. 12(2-3): p. 128-34.
88. Taylor, A.M., et al., *Use of the intravascular contrast agent NC100150 injection in spin-echo and gradient-echo imaging of the heart*. J Cardiovasc Magn Reson, 1999. 1(1): p. 23-32.
89. Schmitz, S.A., et al., *Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe heritable hyperlipidemic rabbits*. Invest Radiol, 2000. 35(8): p. 460-71.